A detailed history of Advisor Group Holdings, Inc. transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 1,200 shares of ANVS stock, worth $6,792. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,200
Previous 1,275 5.88%
Holding current value
$6,792
Previous $7,000 28.57%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$5.27 - $15.46 $395 - $1,159
-75 Reduced 5.88%
1,200 $9,000
Q2 2024

Aug 13, 2024

BUY
$4.82 - $18.01 $361 - $1,350
75 Added 6.25%
1,275 $7,000
Q3 2023

Nov 13, 2023

SELL
$9.37 - $14.12 $8,957 - $13,498
-956 Reduced 44.34%
1,200 $11,000
Q1 2023

May 12, 2023

SELL
$12.33 - $22.1 $14,919 - $26,741
-1,210 Reduced 35.95%
2,156 $33,000
Q4 2022

Feb 10, 2023

BUY
$10.99 - $13.8 $945 - $1,186
86 Added 2.62%
3,366 $45,000
Q3 2022

Nov 14, 2022

BUY
$10.26 - $21.81 $12,414 - $26,390
1,210 Added 58.45%
3,280 $45,000
Q2 2022

Aug 10, 2022

SELL
$8.61 - $13.87 $6,888 - $11,096
-800 Reduced 27.87%
2,070 $25,000
Q1 2022

May 04, 2022

SELL
$11.84 - $19.78 $96,282 - $160,850
-8,132 Reduced 73.91%
2,870 $38,000
Q3 2021

Nov 05, 2021

BUY
$30.95 - $120.97 $286,597 - $1.12 Million
9,260 Added 531.57%
11,002 $349,000
Q2 2021

Aug 02, 2021

SELL
$21.55 - $96.1 $52,969 - $236,213
-2,458 Reduced 58.52%
1,742 $149,000
Q1 2021

May 13, 2021

SELL
$8.15 - $38.44 $26,047 - $122,854
-3,196 Reduced 43.21%
4,200 $117,000
Q4 2020

Feb 10, 2021

SELL
$4.36 - $7.54 $1,909 - $3,302
-438 Reduced 5.59%
7,396 $56,000
Q3 2020

Nov 12, 2020

BUY
$3.84 - $6.78 $28,450 - $50,233
7,409 Added 1743.29%
7,834 $38,000
Q1 2020

May 18, 2020

BUY
$2.66 - $9.59 $1,130 - $4,075
425 New
425 $1,000

Others Institutions Holding ANVS

About Annovis Bio, Inc.


  • Ticker ANVS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,163,920
  • Market Cap $46.2M
  • Description
  • Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...
More about ANVS
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.